Bartels, Karsten
Frendl, Gyorgy
Sprung, Juraj
Weingarten, Toby N.
Subramaniam, Balachundhar
Martinez Ruiz, Ricardo
Lee, Jae-Woo
Henderson, William G.
Moss, Angela
Sodickson, Alissa
Giquel, Jadelis
Vidal Melo, Marcos Francisco
Fernandez-Bustamante, Ana
Amar, David
Bartels, Karsten
Blum, James
Chen, Lee-Lynn
Desiderio, Dawn
Douin, David Josh
Fernandez-Bustamante, Ana
Eikermann, Matthias
Frendl, Gyorgy
Giquel, Jadelis
Grecu, Loreta
Gupta, Ravindra Alok
Karan, Suzanne
Kor, Daryl J.
Lee, Jae-Woo
Martinez Ruiz, Ricardo
Musch, Guido
Sprung, Juraj
Subramaniam, Balachundhar
Sodickson, Alissa
Tanaka, Pedro
Vidal Melo, Marcos Francisco
Wanderer, Jonathan P.
Weingarten, Toby N.
,
Funding for this research was provided by:
National Institute on Drug Abuse (#K23DA040923)
National Heart, Lung, and Blood Institute (#5R34HL123438, #5R34HL123438, #5R34HL123438)
Article History
Received: 30 November 2021
Accepted: 20 April 2022
First Online: 3 May 2022
Declarations
:
: The study protocol was approved at each participating institution by the respective Institutional Review Boards before any study procedures for the original observational study started: the Colorado Multiple Institutional Review Board for the University of Colorado School of Medicine, the Mass General Brigham Institutional Review Board for the Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and Massachusetts General Hospital, the Mayo Clinic Institutional Review Board for the Mayo Clinic, the University of Miami Institutional Review Board for University of Miami, and the University of California San Francisco Institutional Review Board for University of California San Francisco. These Institutional Review Boards granted either a waiver of consent or an opt-out opportunity for the original observational study. The need for informed consent was waived for this secondary analysis of existing data. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: The authors declare no competing interests.